Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Tamoxifen versus etoposid efter første recidiv hos GBM-patienter

2. november 2026 opdateret af: AHS Cancer Control Alberta

Et randomiseret kontrolleret forsøg med tamoxifen versus etoposid til patienter med første tilbagefald af glioblastoma multiforme

The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Jacob Easaw, MD, PhD, FRCPC
  • Telefonnummer: 780-432-8290
  • E-mail: jay.easaw@ahs.ca

Studiesteder

    • Alberta
      • Edmonton, Alberta, Canada
        • Rekruttering
        • Cross Cancer Institute

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Histologically proven GBM with progression after previous first line chemoradiotherapy with temozolomide.

  2. Progression documented by MRI with at least one bi-dimensionally measurable target lesion with one diameter of at least 10 mm, visible on two or more axial slices 5 mm apart.

  3. Not received radiotherapy within the three months before the diagnosis of progression.

  4. Stable or decreasing dose of corticosteroids prior to randomization: corticosteroids (dexamethasone) should be given at the lowest dose needed to control symptoms arising from increased intracerebral edema.

  5. ECOG performance 0-2 (Appendix 2).

  6. Age from 18-65 years.

  7. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.

  8. Patients of childbearing / reproductive potential should use adequate birth control methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.

    Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.

  9. Laboratory evaluation obtained within 7 days prior to randomization, with adequate function as defined below:

    • ANC ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Serum creatinine ≤ 1.5 times ULN
    • Total serum bilirubin ≤ 1.5 times ULN
    • ALT < 3 times ULN
    • AST < 3 times ULN
    • Alkaline phosphatase < 3 times ULN
  10. Patient must understand and sign an informed consent prior to study registration.

Exclusion Criteria:

  1. History of another malignancy or a concurrent malignancy (exceptions include patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
  2. Uncontrolled hypertension (systolic blood pressure >150 mm Hg or diastolic blood pressure >100 mm Hg).
  3. Any arterial or venous thrombosis up to 6 months before registration.
  4. Evidence of recent hemorrhage on brain MRI.
  5. Substantial cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Tamoxifen

Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously

Aktiv komparator: Etoposid

etoposide 50mg/m2 daily

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
3 month progression-free survival
Tidsramme: 3 months

Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.

3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
One-year progression-free survival
Tidsramme: 12 months

Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.

12 months
Overall survival
Tidsramme: Median, 6-month, 1-year, and 2-year OS rates will be measured

Time between randomization and death due to any cause. Patients without an event will be censored the last time they were known to be alive.

Median, 6-month, 1-year, and 2-year OS rates will be measured
Health-related quality-of-life status
Tidsramme: Throughout study completion, up to 5 years.

Health-related quality-of-life will be assessed using the EORTC QLQ-BN20 brain tumor module questionnaire. This is a self-report questionnaire consisting of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit in brain tumor patients

Throughout study completion, up to 5 years.
Adverse events
Tidsramme: Throughout the whole duration of the trial, up to 5 years

This includes fatigue, hematologic toxicities (neutropenia, thrombocytopenia, leukopenia, anemia), liver toxicities, hypertension, diarrhea, seizures and thrombosis and will all be recorded.

Throughout the whole duration of the trial, up to 5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

28. januar 2022

Primær færdiggørelse (Anslået)

1. december 2026

Studieafslutning (Anslået)

1. juli 2027

Datoer for studieregistrering

Først indsendt

18. februar 2021

Først indsendt, der opfyldte QC-kriterier

18. februar 2021

Først opslået (Faktiske)

21. februar 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IIT-0014

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .